Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03351101 · ClinicalTrials.gov registry record · NA

Clinical Study of Approved Contact Lenses

A NA study of Myopia, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
271
Enrollment target
11
Study locations

NCT03351101 is a NA study of Myopia that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 271 participants, roughly in line with the 265-participant average among 90 other Myopia trials with a reported enrollment target. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03351101, a NA study of Myopia, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
271 participants
Enrollment target
11
Study locations

Study Summary

Evaluation of Johnson \& Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch + Lomb Ultra (samfilcon A) soft contact lenses

Conditions Studied

Interventions

  • DEVICE Senofilcon C
  • DEVICE Samfilcon A

Study Locations (11)

Florida

  • Valeant Site 06 - Orlando
  • Valeant Site 01 - Orlando
  • Valeant Site 05 - Sarasota

California

  • valeant Site 02 - San Diego
  • Valeant Site 03 - San Francisco

Colorado

  • Valeant Site 04 - Denver

Kansas

  • Valeant Site 07 - Pittsburg

Missouri

  • Valeant Site 08 - Warrensburg

New York

  • Valeant Site 09 - Vestal

Ohio

  • Valeant Site 10 - Powell

Wisconsin

  • Valeant Site 11 - New Berlin

Trial Details

FieldValue
Enrollment Target 271 participants
Start Date 2017-10-23
Est. Completion 2017-12-08
Phase NA

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT03351101

The ClinicalTrials.gov registry entry for NCT03351101 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 265-participant average among 90 other Myopia trials with a reported enrollment target. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Senofilcon C is the first listed.

NCT03351101 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT03351101 about?

NCT03351101 is a clinical study titled "Clinical Study of Approved Contact Lenses". Evaluation of Johnson \& Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch + Lomb Ultra (samfilcon A) soft contact lenses

What is the current status of trial NCT03351101?

This trial is currently completed. It is a NA study. The enrollment target is 271 participants. The study started on 2017-10-23. Estimated completion is 2017-12-08.

What conditions does trial NCT03351101 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT03351101?

The interventions under investigation include: Senofilcon C (DEVICE), Samfilcon A (DEVICE).

Who is sponsoring clinical trial NCT03351101?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03351101 being conducted?

This trial has 11 study locations across California, Colorado, Florida, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.